Spero Therapeutics (NASDAQ:SPRO) Insider Sells $42,485.04 in Stock

by · The Markets Daily

Spero Therapeutics, Inc. (NASDAQ:SPRO – Get Free Report) insider Esther Rajavelu sold 40,851 shares of the business’s stock in a transaction on Monday, November 9th. The stock was sold at an average price of $1.04, for a total transaction of $42,485.04. Following the completion of the transaction, the insider directly owned 946,000 shares in the company, valued at $983,840. This trade represents a 4.14% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Spero Therapeutics Stock Down 5.6%

NASDAQ SPRO traded down $0.06 on Tuesday, reaching $1.01. The company had a trading volume of 183,743 shares, compared to its average volume of 782,123. The stock has a market capitalization of $58.82 million, a PE ratio of 9.18 and a beta of 1.59. The firm’s 50 day moving average price is $1.15 and its 200 day moving average price is $1.94. Spero Therapeutics, Inc. has a 12 month low of $0.96 and a 12 month high of $3.08.

Spero Therapeutics (NASDAQ:SPRO – Get Free Report) last issued its quarterly earnings data on Wednesday, August 12th. The company reported ($0.16) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.17) by $0.01. Spero Therapeutics had a return on equity of 16.17% and a net margin of 24.90%. On average, research analysts expect that Spero Therapeutics, Inc. will post -0.97 EPS for the current year.

Wall Street Analysts Forecast Growth

SPRO has been the subject of a number of recent research reports. HC Wainwright lifted their price objective on shares of Spero Therapeutics from $5.00 to $6.00 and gave the stock a “buy” rating in a research note on Monday, September 14th. Wall Street Zen downgraded Spero Therapeutics from a “hold” rating to a “sell” rating in a research report on Saturday, October 31st. Zacks Research raised shares of Spero Therapeutics to a “hold” rating in a research note on Monday, September 14th. Cantor Fitzgerald began coverage on shares of Spero Therapeutics in a research report on Wednesday, October 28th. They set an “overweight” rating and a $6.00 price objective on the stock. Finally, Weiss Ratings downgraded shares of Spero Therapeutics from a “hold (c-)” rating to a “sell (d+)” rating in a research note on Monday, October 26th. Two research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, Spero Therapeutics presently has a consensus rating of “Hold” and an average target price of $6.00.

View Our Latest Report on Spero Therapeutics

Institutional Investors Weigh In On Spero Therapeutics

Several hedge funds have recently made changes to their positions in the company. Alphabet Inc. bought a new position in Spero Therapeutics during the 2nd quarter worth about $1,967,000. BlackRock Inc. purchased a new position in Spero Therapeutics during the second quarter valued at approximately $1,314,000. GSA Capital Partners LLP bought a new position in Spero Therapeutics in the second quarter worth approximately $632,000. Global Retirement Partners LLC bought a new position in shares of Spero Therapeutics in the 2nd quarter worth $55,000. Finally, Susquehanna Fundamental Investments LLC bought a new position in shares of Spero Therapeutics in the 2nd quarter worth $36,000. 25.60% of the stock is currently owned by hedge funds and other institutional investors.

Spero Therapeutics Company Profile

(Get Free Report)

Spero Therapeutics, Inc. (NASDAQ:SPRO) is a biopharmaceutical company focused on developing treatments for multidrug-resistant bacterial infections and certain rare diseases. The company’s research programs are designed to address infections for which existing antibiotics may be inadequate, including complicated urinary tract infections and infections caused by difficult-to-treat pathogens. Spero’s lead product candidate has been tebipenem pivoxil hydrobromide, an orally administered carbapenem antibiotic developed for the treatment of complicated urinary tract infections.

See Also